drugset / Trial / NCT03322124
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation. The study will consist of a 14-day screening period and a 5-day treatment period.
Timeline
- Start
- 2018-01-22
- Primary completion
- 2018-12-14
- Completion
- 2018-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octenidinedihydrochlorid | Unknown | 0.1 % | Other |
| Subject | Octenidinedihydrochlorid | Unknown | 10 ml | Other |
Indications
No indication recorded.